Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors

[1]  G. Schultz,et al.  Adenylate cyclase inhibition and GTPase stimulation by somatostatin in S49 lymphoma cyc− variants are prevented by islet‐activating protein , 1983, FEBS letters.

[2]  P. Canonico,et al.  The inhibition of phosphatidylinositol turnover: a possible postreceptor mechanism for the prolactin secretion-inhibiting effect of dopamine. , 1983, Endocrinology.

[3]  G. Schultz,et al.  A nucleotide regulatory site for somatostatin inhibition of adenylate cyclase in S49 lymphoma cells , 1983, Nature.

[4]  J. Peters,et al.  Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin. , 1983, Endocrinology.

[5]  M. Cronin,et al.  Adenosine 3',5'-monophosphate (cAMP) and calcium-calmodulin interrelation in the control of prolactin secretion: evidence for dopamine inhibition of cAMP accumulation and prolactin release after calcium mobilization. , 1983, Endocrinology.

[6]  J. Bockaert,et al.  Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. , 1983, Molecular pharmacology.

[7]  D. Sibley,et al.  Regulation of ligand binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. , 1983, The Journal of biological chemistry.

[8]  D. Sibley,et al.  Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. , 1983, Molecular Pharmacology.

[9]  J. Daly,et al.  Guanosine 5'-(beta, gamma-imido)triphosphate inhibition of forskolin-activated adenylate cyclase is mediated by the putative inhibitory guanine nucleotide regulatory protein. , 1982, The Journal of biological chemistry.

[10]  M. Caron,et al.  Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists. , 1982, Molecular pharmacology.

[11]  J. Wolff,et al.  Forskolin stimulation of thyroid adenylate cyclase and cyclic 3',5'-adenosine monophosphate accumulation. , 1982, Endocrinology.

[12]  L. Forte,et al.  Alpha-2 adrenergic activation inhibits forskolin-stimulated adenylate cyclase activity and lipolysis in human adipocytes. , 1982, Life sciences.

[13]  C. Denef,et al.  Physiological concentrations of dopamine decrease adenosine 3',5'-monophosphate levels in cultured rat anterior pituitary cells and enriched populations of lactotrophs: evidence for a causal relationship to inhibition of prolactin release. , 1982, Endocrinology.

[14]  P. Insel,et al.  Regulation of adenylate cyclase of human platelet membranes by forskolin. , 1982, The Journal of biological chemistry.

[15]  K. Ray,et al.  Actions of dopamine on prolactin secretion and cyclic AMP metabolism in ovine pituitary cells , 1982, Molecular and Cellular Endocrinology.

[16]  D. Sibley,et al.  Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.

[17]  J. Daly,et al.  Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. , 1982, Molecular pharmacology.

[18]  D. Cooper.  Bimodal regulation of adenylate cyclase , 1982, FEBS letters.

[19]  P. Dannies,et al.  The role of adenosine 3',5'-monophosphate in dopaminergic inhibition of prolactin release in anterior pituitary cells. , 1981, Endocrinology.

[20]  G. Giannattasio,et al.  Dopamine-inhibited adenylate cyclase in female rat adenohypophysis. , 1981, Life sciences.

[21]  J. Fain,et al.  Alpha 2 adrenergic amines, adenosine and prostaglandins inhibit lipolysis and cyclic AMP accumulation in hamster adipocytes in the absence of extracellular sodium. , 1981, Life sciences.

[22]  J. T. Hackett,et al.  Calcium rather than cyclic AMP as the physiological intracellular regulator of prolactin release. , 1980, Neuroendocrinology.

[23]  R. Lefkowitz,et al.  A high affinity agonist . beta-adrenergic receptor complex is an intermediate for catecholamine stimulation of adenylate cyclase in turkey and frog erythrocyte membranes. , 1980, The Journal of biological chemistry.

[24]  M. Steer,et al.  Regulation of human platelet adenylate cyclase by epinephrine, prostaglandin E1, and guanine nucleotides. Evidence for separate guanine nucleotide sites mediating stimulation and inhibition. , 1979, The Journal of biological chemistry.

[25]  L. Frohman,et al.  Prolactin-suppressive effects of two aminotetralin analogs of dopamine: their use in the characterization of the pituitary dopamine receptor. , 1979, Endocrinology.

[26]  P. Camilli,et al.  Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas , 1979, Nature.

[27]  J. C. Porter,et al.  Release of newly synthesized dopamine into the hypophysial portal vasculature of the rat. , 1979, Endocrinology.

[28]  W. Douglas,et al.  Catecholamines of supposed inhibitory hypophysiotrophic function suppress action potentials in prolactin cells , 1978, Nature.

[29]  J. Roberts,et al.  Dopamine and dihydroergocryptine binding to the anterior pituitary and other brain areas of the rat and sheep. , 1978, Endocrinology.

[30]  J. D. Neill,et al.  Dopamine levels in hypophysial stalk blood in the rat are sufficient to inhibit prolactin secretion in vivo. , 1978, Endocrinology.

[31]  M. Caron,et al.  Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. , 1978, The Journal of biological chemistry.

[32]  C. Oliver,et al.  Dopamine in hypophysial portal plasma of the rat during the estrous cycle and throughout pregnancy. , 1977, Endocrinology.

[33]  R. Macleod,et al.  Dibutyryl cyclic AMP, adenosine and guanosine blockade of the dopamine, ergocryptine and apomorphine inhibition of prolactin release in vitro. , 1976, Endocrinology.

[34]  R. Macleod,et al.  Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. , 1974, Endocrinology.

[35]  C. Londos,et al.  A highly sensitive adenylate cyclase assay. , 1974, Analytical biochemistry.

[36]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[37]  H. Nagasawa,et al.  Promotion of pituitary prolactin release in rats by dibutyryl adenosine 3',5'-monophosphate. , 1972, The Journal of endocrinology.

[38]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[39]  G. Giannattasio,et al.  In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. , 1983, The Journal of clinical endocrinology and metabolism.